NCT02394652View on ClinicalTrials.gov

The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

January 12, 2021

Study Completion Date

January 12, 2021

Conditions

Uterine Cervical NeoplasmsSquamous Cell CarcinomaAdenocarcinomaCarcinoma, Adenosquamous

Interventions

DRUG

Metformin

Metformin is an antidiabetic agent given orally.

DRUG

Cisplatin

Cisplatin is an antineoplastic agent given intravenously.

DRUG

FAZA

FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.

Trial Locations (5)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

H2L 4M1

Centre Hospitalier De L'Université de Montréal, Montreal

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT02394652 - The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | Biotech Hunter | Biotech Hunter